Corneal Defect
9
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery
Feasibility Investigation of Biometry and Tomography Measurements in a Heterogeneous Patient Cohort
Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects
The Germinal Peptide Eye Drops in Healthy Volunteers in a Clinical Study
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers